Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Verve Therapeutics to $55 from $56 and keeps a Buy rating on the shares. Verve reported Q2 results, with the VERVE-101 heart-1 trial on track for initial data in Q4 and VERVE-102 and VERVE-201 Phase 1 trials set to initiate in 1H24 and 2H24, respectively, the analyst tells investors in a research note. The firm sees particular value in the VERVE-102 program with the advantage of more selective targeting and potentially higher editing rates while utilizing the same GalNAc platform as VERVE-201.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics reports Q2 EPS (87c), consensus (92c)
- Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
- Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
- Cathie Wood’s ARK Investment bought 96.3K shares of Verve Therapeutics today
- Cathie Wood’s ARK Investment bought 69K shares of Verve Therapeutics today